[HTML][HTML] Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials: a collaborative systematic review and meta-analysis
Z Wu, Q Chen, L Qu, M Li, L Wang, MC Mir… - European urology, 2022 - Elsevier
Context Therapies based on immune checkpoint inhibitors (ICIs) are transforming the
treatment landscape of urologic oncology. Nevertheless, an exhaustive overview of the …
treatment landscape of urologic oncology. Nevertheless, an exhaustive overview of the …
[HTML][HTML] The role of the tumor microbiome in tumor development and its treatment
Y Chen, FH Wu, PQ Wu, HY Xing, T Ma - Frontiers in Immunology, 2022 - frontiersin.org
Commensal bacteria and other microorganisms that reside in the human body are closely
associated with the development and treatment of cancers. Recently, tumor microbiome …
associated with the development and treatment of cancers. Recently, tumor microbiome …
Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
T Powles, BP Valderrama, S Gupta… - … England Journal of …, 2024 - Mass Medical Soc
Background No treatment has surpassed platinum-based chemotherapy in improving
overall survival in patients with previously untreated locally advanced or metastatic …
overall survival in patients with previously untreated locally advanced or metastatic …
Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial
Abstract Purpose: The PURE-01 study (NCT02736266) pioneered the neoadjuvant immune-
checkpoint inhibitor (ICI) therapy before radical cystectomy (RC) in patients with muscle …
checkpoint inhibitor (ICI) therapy before radical cystectomy (RC) in patients with muscle …
Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after≥ 2 years of follow-up
T Powles, SH Park, C Caserta… - Journal of Clinical …, 2023 - ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …
report, typically based on the primary end point, may be published when key planned …
[HTML][HTML] Molecular landscape of LncRNAs in bladder cancer: from drug resistance to novel LncRNA-based therapeutic strategies
A Mehmandar-Oskuie, K Jahankhani… - Biomedicine & …, 2023 - Elsevier
Bladder cancer (BC) is a common and serious type of cancer that ranks among the top ten
most prevalent malignancies worldwide. Due to the high occurrence rate of BC, the …
most prevalent malignancies worldwide. Due to the high occurrence rate of BC, the …
Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial …
T Powles, ZJ Assaf, V Degaonkar, P Grivas, M Hussain… - European urology, 2024 - Elsevier
Abstract Background Interim results from IMvigor010 showed an overall survival (OS) benefit
for adjuvant atezolizumab (anti–PD-L1) versus observation in patients with circulating tumor …
for adjuvant atezolizumab (anti–PD-L1) versus observation in patients with circulating tumor …
[HTML][HTML] Advances in diagnosis and therapy for bladder cancer
X Hu, G Li, S Wu - Cancers, 2022 - mdpi.com
Simple Summary The clinical management of bladder cancer has been developing in the
past decade, including diagnostic tools and treatment options. Both monotherapy and …
past decade, including diagnostic tools and treatment options. Both monotherapy and …
Hyaluronic acid-conjugated fluorescent probe-shielded polydopamine nanomedicines for targeted imaging and chemotherapy of bladder cancer
H Qiu, J Wang, Y Zhi, B Yan, Y Huang, J Li… - … Applied Materials & …, 2023 - ACS Publications
Bladder cancer is one of the most common malignancies in the urinary system, with high risk
of recurrence and progression. However, the difficulty in detecting small tumor lesions and …
of recurrence and progression. However, the difficulty in detecting small tumor lesions and …
[HTML][HTML] Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for …
P Grivas, E Kopyltsov, PJ Su, FX Parnis, SH Park… - European Urology, 2023 - Elsevier
Abstract Background In JAVELIN Bladder 100, avelumab first-line maintenance plus best
supportive care (BSC) significantly prolonged overall survival (OS; primary endpoint) versus …
supportive care (BSC) significantly prolonged overall survival (OS; primary endpoint) versus …